Myocardial Regeneration via Progenitor Cell-Derived Exosomes
In the past 20 years, a variety of cell products has been evaluated in terms of their capacity to treat patients with acute myocardial infarction and chronic heart failure. Despite initial enthusiasm, therapeutic efficacy has overall been disappointing, and clinical application is costly and complex...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2017/7849851 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832568391243661312 |
|---|---|
| author | Janita A. Maring Christien M. Beez Volkmar Falk Martina Seifert Christof Stamm |
| author_facet | Janita A. Maring Christien M. Beez Volkmar Falk Martina Seifert Christof Stamm |
| author_sort | Janita A. Maring |
| collection | DOAJ |
| description | In the past 20 years, a variety of cell products has been evaluated in terms of their capacity to treat patients with acute myocardial infarction and chronic heart failure. Despite initial enthusiasm, therapeutic efficacy has overall been disappointing, and clinical application is costly and complex. Recently, a subset of small extracellular vesicles (EVs), commonly referred to as “exosomes,” was shown to confer cardioprotective and regenerative signals at a magnitude similar to that of their donor cells. The conceptual advantage is that they may be produced in industrial quantities and stored at the point-of-care for off-the-shelf application, ideally without eliciting a relevant recipient immune response or other adverse effects associated with viable cells. The body of evidence on beneficial exosome-mediated effects in animal models of heart diseases is rapidly growing. However, there is significant heterogeneity in terms of exosome source cells, isolation process, therapeutic dosage, and delivery mode. This review summarizes the current state of research on exosomes as experimental therapy of heart diseases and seeks to identify roadblocks that need to be overcome prior to clinical application. |
| format | Article |
| id | doaj-art-e1dfe7420ccf4aa490b968af6a6a1c71 |
| institution | Kabale University |
| issn | 1687-966X 1687-9678 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-e1dfe7420ccf4aa490b968af6a6a1c712025-02-03T00:59:16ZengWileyStem Cells International1687-966X1687-96782017-01-01201710.1155/2017/78498517849851Myocardial Regeneration via Progenitor Cell-Derived ExosomesJanita A. Maring0Christien M. Beez1Volkmar Falk2Martina Seifert3Christof Stamm4Berlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, GermanyBerlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, GermanyGerman Center for Cardiovascular Research (DZHK), Partner Site Berlin, Berlin, GermanyBerlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, GermanyBerlin-Brandenburg Center for Regenerative Therapies (BCRT), Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, GermanyIn the past 20 years, a variety of cell products has been evaluated in terms of their capacity to treat patients with acute myocardial infarction and chronic heart failure. Despite initial enthusiasm, therapeutic efficacy has overall been disappointing, and clinical application is costly and complex. Recently, a subset of small extracellular vesicles (EVs), commonly referred to as “exosomes,” was shown to confer cardioprotective and regenerative signals at a magnitude similar to that of their donor cells. The conceptual advantage is that they may be produced in industrial quantities and stored at the point-of-care for off-the-shelf application, ideally without eliciting a relevant recipient immune response or other adverse effects associated with viable cells. The body of evidence on beneficial exosome-mediated effects in animal models of heart diseases is rapidly growing. However, there is significant heterogeneity in terms of exosome source cells, isolation process, therapeutic dosage, and delivery mode. This review summarizes the current state of research on exosomes as experimental therapy of heart diseases and seeks to identify roadblocks that need to be overcome prior to clinical application.http://dx.doi.org/10.1155/2017/7849851 |
| spellingShingle | Janita A. Maring Christien M. Beez Volkmar Falk Martina Seifert Christof Stamm Myocardial Regeneration via Progenitor Cell-Derived Exosomes Stem Cells International |
| title | Myocardial Regeneration via Progenitor Cell-Derived Exosomes |
| title_full | Myocardial Regeneration via Progenitor Cell-Derived Exosomes |
| title_fullStr | Myocardial Regeneration via Progenitor Cell-Derived Exosomes |
| title_full_unstemmed | Myocardial Regeneration via Progenitor Cell-Derived Exosomes |
| title_short | Myocardial Regeneration via Progenitor Cell-Derived Exosomes |
| title_sort | myocardial regeneration via progenitor cell derived exosomes |
| url | http://dx.doi.org/10.1155/2017/7849851 |
| work_keys_str_mv | AT janitaamaring myocardialregenerationviaprogenitorcellderivedexosomes AT christienmbeez myocardialregenerationviaprogenitorcellderivedexosomes AT volkmarfalk myocardialregenerationviaprogenitorcellderivedexosomes AT martinaseifert myocardialregenerationviaprogenitorcellderivedexosomes AT christofstamm myocardialregenerationviaprogenitorcellderivedexosomes |